Special Issue "Non-Coding RNA, Fibrogenesis, and Fibrotic Disease"
A special issue of Non-Coding RNA (ISSN 2311-553X).
Deadline for manuscript submissions: closed (31 January 2019) | Viewed by 20771
Interests: ncRNA; epigenetics; nonalcoholic fatty liver disease; hepatic fibrosis; microvascular complications of type 2 diabetes; gene expression
Fibrosis describes the accumulation of extracellular matrix proteins in response to injury. Under pathological conditions, such as chronic inflammation, fibrosis results in scarring of the affected tissue and compromises normal organ function. Fibrosis affects a wide range of organs, resulting in diseases such as nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), cystic fibrosis, atrial fibrosis, and renal fibrosis. Accumulating evidence suggests that fibrosis may be reversible in some organs; however, the mechanisms underlying this process remain incompletely elucidated. In other organs, such as lung, fibrosis is not curable and the prognosis for IPF patients is dismal. Further, the clinical course of fibrotic disease is heterogeneous and methods for predicting disease trajectory are lacking. In some organs, fibrotic disease oftentimes manifests symptoms past the point where treatment strategies are effective, yet non-invasive methods for the accurate detection of fibrosis are not yet available in many tissues. Given the significant clinical impact of fibrotic disease, efforts to understand the development and progression of fibrosis across myriad tissues and organs represent an active area of research.
Recent work has shown a role for non-coding RNA (ncRNA) in the pathogenesis and progression of fibrotic disease. The potential of ncRNAs to serve as biomarkers and targets for drug development in fibrotic disease is also becoming more fully appreciated. For this Special Issue, we invite colleagues exploring the intersection between ncRNAs and fibrotic disease to submit original research, methods, and review manuscripts on the role and function of miRNAs, lncRNAs, and other ncRNAs in the development, regulation, and reversal of fibrosis, as well as the clinical utility of ncRNAs in the diagnosis, prognosis, or treatment of fibrotic diseases.
Prof. Johanna K. DiStefano
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Non-Coding RNA is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- fibrotic disease
- hepatic fibrosis
- cystic fibrosis
- idiopathic pulmonary fibrosis
- atrial fibrosis